论文部分内容阅读
近年,NK细胞的活化性受体NKG2D已成为研究热点,作为NKG2D配体的MICA(人类MHC-Ⅰ类分子链相关基因A)蛋白越来越受关注。机体内MICA以膜型和分泌型两种形式存在。膜型MICA与NKG2D相互作用在肿瘤免疫监视中起着非常重要的作用;与此相反,分泌型MICA不仅下调NKG2D受体的表达,而且下调其细胞毒活性,对免疫细胞抗肿瘤起阻碍作用,可能是肿瘤免疫逃逸的一种新的机制。因此,可以利用这些特点发挥MICA蛋白在肿瘤生物治疗中的应用价值。
In recent years, NK cell activation receptor NKG2D has become a research hotspot, as a ligand of MICA NKG2D (human MHC class I molecular chain related gene A) protein more and more attention. MICA to membrane and secretory two forms exist in the body. Membrane-type MICA and NKG2D interactions play an important role in tumor immune surveillance. In contrast, secreted MICA not only down-regulates the expression of NKG2D receptor but also down-regulates its cytotoxic activity, which hinders immune cells against tumor. It may be a new mechanism of tumor immune escape. Therefore, we can take advantage of these characteristics to exert the value of MICA protein in tumor biotherapy.